Although initial findings suggest that GLP-1Ra leads to a slight reduction in bone mineral density and promotes bone remodeling, favoring resorption similar to calorie restriction effects, further research is needed to explore the effects of GLP-1Ra on bone metabolism and fracture-related outcomes, as well as dual- and triple-receptor agonists of GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon in PwO
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells
Per one study, doses of about 50100 mg/kg/day are generally well tolerated
The New York drug giant will go up against other big pharmas in the world's second-most populous country by lining up a deal with Sciwind Biosciences for its recently approved GLP-1 injectable called ecnoglutide
While receptor levels, animal diet, dosing, and the presence of a GLP-1RA have a profound impact on insulin secretion and associated endocrine outcomes, the effects of dual or triple agonism of Y1-R and Y2-R, in the presence of a GLP-1RA remain unclear
